

BESTNPET INC.
CONDENSED FINANCIAL STATEMENTS FOR THE PERIOD ENDING MARCH 31, 2018
AND CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017

	Page
Condensed and Condensed Consolidated Balance Sheets	F-1
Condensed and Condensed Consolidated Statements of Operations and Comprehensive Income	F-2
Condensed and Consolidated Statements of Stockholders Deficit	F-3
Condensed and Consolidated Statements of Cash Flows	F-4
Notes to Condensed and Consolidated Financial Statements	F-5 – F-17

BestnPet, Inc.
(A Development stage company)
Condensed and Consolidated Balance Sheets
(Unaudited)

	March 31, 2018 \$ (Consolidated)	2017 \$ (Consolidated)
Current Assets		
Cash and cash equivalents	17,347	-
Advance on business transaction	-	-
Accounts receivable	27,820	-
Inventory	66,134	-
Prepaid and others current assets	2,574	-
Total current assets	113,876	-
Property and Equipment		
Accumulated depreciation	-	(1,690)
Computer equipment	-	1,690
Total property and equipment	-	-
Other Assets		
Accumulated amortization	-	-
Intangible asset, net	-	-
Total other assets	-	-
Total assets	\$ 113,875	\$ -

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current Liabilities		
Accounts payable and accrued expenses	\$ 64,324	\$ -
Accrued interest	-	-
Related party payable	-	-
Derivative liability	-	-
Convertible note payable, net	112,418	-
Payable on purchase	-	-
Payroll payable	-	-
Other payable	182,935	4,705
Total current liabilities	359,677	4,705
Total liabilities	359,677	4,705
Commitments and Contingencies		
	-	-
Stockholders' Equity (Deficit)		
Common stock, \$.001 par value, 412,000,000 shares authorized; 41,446,000 and 41,446,000 shares issued and outstanding, respectively	120,242	41,446
Additional paid-in capital	2,757,758	2,826,554
Accumulated deficit	(3,123,802)	(2,872,705)
Translation adjustment	-	-
Total stockholders' equity (deficit)	(245,802)	(4,705)
Total liabilities and stockholders' equity (deficit)	113,875	-

The accompanying notes are an integral part of these financial statements.

BestnPet, Inc.
(A Development Stage Company)
Condensed and Consolidated Statements of Operations
(Unaudited)

	March 31, 2018	2017
	\$	\$ (Consolidated)
Revenue	30,869	-
Cost of Goods Sold	22,960	-
Gross Profit	7,909	-
Operating Expenses		
Bad debt	-	2,104,923
Operation and administration	188,325	4,705
Total operating expense	188,325	2,109,628
Net loss from operations	(180,416)	(2,109,628)
Other income (expense)		
Interest income	-	-
Interest expense	-	(2,746)
Forgiveness of debit	-	1,506,693
Loss on derivative liability	-	864,713
Total other income (expense)	-	2,368,660
Net loss prior to income tax	(180,416)	259,032
Income tax expense	-	-
Net income (loss)	(180,416)	259,032
Gain (loss) translation adjustment foreign exchange	-	-
Comprehensive net income (loss)	(180,416)	259,032
Loss per common share - basic and fully diluted	0.00	(0.00)
Weighted average common shares - basic and fully diluted	120,242,000	41,446,000

The accompanying notes are an integral part of these financial statements.

BestnPet , Inc.**(A Development Stage Company)**

Statements of Stockholders' (Deficiency)Equity

For the years ended December 31, 2017 and 2016

	<u>Common Stock</u>		<u>Additional</u>	<u>Translation</u>	<u>Accumulated</u>	<u>Total</u>
	<u>Shares</u>	<u>Amount</u>	<u>Paid-in</u>	<u>adjustment</u>	<u>Deficit During</u>	<u>Stockholders'</u>
			<u>Capital</u>		<u>Development</u>	<u>Deficit</u>
					<u>Stage</u>	
Balance, December 31, 2016	<u>41,446,000</u>	<u>41,446</u>	<u>1,722,980</u>	<u>39,342</u>	<u>(4,190,890)</u>	<u>(2,387,122)</u>
Demerger of subsidiaries adjustment	-	-	1,103,574	-	-	1,103,574
Demerger of subsidiaries adjustments	-	-	-	-	1,059,152	1,059,152
Translation adjustment				(39,342)		(39,342)
Net loss for year ending December 31, 2017	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>259,033</u>	<u>259,033</u>
Balance, December 31, 2017	<u>41,446,000</u>	<u>41,446</u>	<u>2,826,554</u>	<u>-</u>	<u>(2,872,705)</u>	<u>(4,705)</u>
Adjustment of number of shares	158,000	158	(158)	-	-	-
Merger (exchange of shares and loss)	100,000,000	100,000		-	(70,681)	29,319
Cancellation of shares for merger	(21,362,000)	(21,362)	21,362	-		-
Exchange of shares adjustment	-		(90,000)	-	-	(90,000)
Net loss for period ending March 31, 2018	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(180,416)</u>	<u>(180,416)</u>
Balance, March 31, 2018	<u>120,242,000</u>	<u>120,242</u>	<u>2,757,758</u>	<u>-</u>	<u>(3,123,802)</u>	<u>(245,802)</u>

The accompanying notes are an integral part of these financial statements.

BestnPet, Inc.
(A Development Stage Company)
Cash Flow Statement
(Unaudited)

	March 31, 2017 \$ (Consolidated)	2017 \$ (Consolidated)
Cash flows from operating activities		
Net loss	(180,416)	259,032
Adjustments to reconcile net income (loss) to net cash used in operating activities		
Bad debt	-	2,104,923
Loss on derivative liability	-	(864,713)
Amortization	-	-
Changes in operating assets and liabilities:		
Increase in accounts receivable	(27,820)	-
Increase in inventory	(23,582)	-
Increase in prepaid and others	(825)	-
Decrease in intangible asset, net	-	-
Increase in accounts payable and accrued expenses	64,324	(356,149)
Decrease in accrued interest	-	(30,903)
Decrease in related party payable	-	(191,895)
Increase in convertible note payable, net	22,418	(925,000)
Decrease in payable on purchase	-	-
Decrease in payroll payable	-	-
Increase in other payable	142,071	4,705
Net cash provided by (used in) operating activities	<u>(3,830)</u>	<u>-</u>
Cash flows from investing activities		
Adjustment for merger of subsidiaries	-	-
Cash paid for equipment	-	-
Net cash used in investing activities	<u>-</u>	<u>-</u>
Cash flows from financing activities		
Net cash provided by financing activities	<u>-</u>	<u>-</u>
Effect of exchange rate changes on cash	-	-
Increase in cash and cash equivalents	(3,830)	-
Cash and cash equivalents, beginning of year	<u>21,177</u>	<u>-</u>
Cash and cash equivalents, end of period	<u>\$ 17,347</u>	<u>\$ -</u>

The accompanying notes are an integral part of these financial statements.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

Note 1 – Nature of Operations

The Company was incorporated in the State of Nevada on June 23, 2009. On June 22, 2011, the Company changed the name to Pequot Resources, Inc. Effective January 9, 2013, the Company changed its name to “Resolute Oncology Inc.”, by way of a merger with its wholly-owned subsidiary Resolute Oncology Inc., which was formed solely for the change of name. The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on January 9, 2013. The Company acquired a mineral property located in the Sudbury Mining District, within the province of Ontario, Canada and has not determined whether this property contains reserves that are economically recoverable. The recoverability of property expenditures will be dependent upon the discovery of economically recoverable reserves, confirmation of the Company’s interest in the underlying property, and the ability of the Company to obtain necessary financing to satisfy the expenditure requirements under the property agreement and upon future profitable production of proceeds for sale thereof.

The Company has evaluated the above mining interest and has decided not to further develop the mining property.

On December 17, 2012, the Company incorporated a wholly owned subsidiary, Resolute Oncology Limited, an Ireland corporation, for the purpose of managing the potential operations in Europe. Resolute Oncology Limited operations began on January 1, 2013.

Effective January 9, 2013, we changed our name from “Pequot Resources, Inc.” to “Resolute Oncology Inc.”, by way of a merger with our wholly-owned subsidiary Resolute Oncology Inc., which was formed solely for the change of name. The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on January 9, 2013 under our company’s new symbol “REON”. As at the date of this quarterly report, we have not entered into any definitive agreement regarding the potential transaction and there is no certainty that we will do so.

On February 4, 2013, we effected a forward split of our authorized, issued and outstanding shares of common stock on a 5.5 new for one old basis, such that our authorized capital increased from 75,000,000 to 412,500,000 shares of common stock and correspondingly, our issued and outstanding shares of common stock increased from 6,800,000 to 37,400,000 common shares, all with a par value of \$0.001. Our new stock symbol is “REON”.

On April 12, 2013, we completed due diligence and finalized a license agreement dated March 24, 2013 with Reliance Life Sciences Limited (RLS), an pharmaceutical company incorporated under the laws of India, pursuant to which we acquired certain rights to RLS’ bio-similar therapeutic protein product referred to as Pegylated Granulocyte Colony-Stimulating Factor (Peg-G-CSF or PEG-Filgrastim). Pursuant to the agreement RLS has agreed to transfer and license to our company the exclusive right to develop and commercialize RLS’ PEG-Filgrastim in North America (U.S., Canada, and Mexico) and the European Union. RLS will manufacture and supply clinical formulations and commercial supplies of the product while we will be responsible for managing the regulatory approval process. The term of the license shall be 10 years from the date of market approval in each applicable territory. Subject to any mutually agreed renewals, the license term will automatically renew for an additional 2 years. In consideration for product license and related rights, we have paid a total of \$500,000 to date. Additional fees of \$6,000,000 in the aggregate will be due to Reliance Life Sciences upon successful completion of certain clinical and commercial milestones as follows:

- \$500,000 upon completion of Phase I and II clinical studies;
- \$1,000,000 upon completion of Phase II registration studies;
- \$1,000,000 upon market approval in the U.S.;
- \$300,000 upon market approval in EU;
- \$100,000 upon market approval in Canada;
- \$100,000 upon market approval in Mexico;
- \$2,000,000 within 30 days of first commercial sales in North America;
- \$1,000,000 within 30 days of first commercial sales in any European country.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

We will also pay to RLS a 4% quarterly net sales royalty on all sales of licensed products. The license agreement may be terminated by either party upon 30 days' notice in the event of default by the other party that remains uncured for 60 days, upon the continuation of an event of force majeure for 90 days, or in the event of the insolvency or bankruptcy of the other party.

On May 8, 2013 we and our wholly owned Irish subsidiary, Resolute Oncology Ltd. entered into and closed a Sale and Purchase and Assignment Agreement (the "Purchase Agreement") with Oncocorp GmbH, Peter Gotzler, and Resolute Oncology GmbH ("Resolute Germany"). Pursuant to the terms of the agreement, we acquired, through Resolute Ireland, all issued and outstanding shares and assets of Resolute Germany from Oncocorp GmbH. In full consideration of the transaction, we agreed to pay to Oncocorp GmbH €500,000 (approximately USD\$667,000) in cash and the issuance of 1,000,000 common shares in Resolute Oncology valued at \$0.50 cents per share. We issued the securities to one non "U.S. person" in an "offshore transaction" (at those terms term are defined in Regulation S of the Securities Act of 1933), relying on Regulation S and/or Section 4(2) of the Securities Act of 1933. As a result of the transaction, we had 41,386,000 issued and outstanding common shares as at the date of this Current Report. The cash component of the consideration is payable in six installments as follows:

- €250,000 (approximately USD\$333,500) payable within seven days of the agreement (which amount has been paid);
- €50,000 (approximately USD\$66,700) payable on July 15, 2013(which payment has been deferred by verbal agreement of the parties until a mutually agreeable date)
- €50,000 payable on August 15, 2013 (which payment has been deferred by verbal agreement of the parties until a mutually agreeable date);
- €50,000 payable on September 15, 2013(which payment has been deferred by verbal agreement of the parties until a mutually agreeable date);
- €50,000 payable on October 15, 2013(which payment has been deferred by verbal agreement of the parties until a mutually agreeable date); and
- €50,000 payable on November 15, 2013(which payment has been deferred by verbal agreement of the parties until a mutually agreeable date);

These payments have been deferred by verbal agreement of the parties until a mutually agreeable date.

Any late payments in respect of the cash consideration will accrue interest at a per annum rate of 1,000 basis points above the Euro Interbank Offered Rate (EURIBOR). Oncocorp may not dispose or encumber the 1,000,000 consideration shares for a period of twelve months from issuance.

The rights of Oncocorp to the unpaid portion of the purchase price are secured against the common shares of Resolute Germany pursuant to the Share Pledge Agreement dated concurrently with the Purchase and Assignment Agreement.

As material terms of the Purchase Agreement we have agreed to enter into the following material agreements:

- Supply Agreement with Oncocorp GmbH for the supply of Oncocorp's Paclitaxel OC to our Company;
- Option Agreement for the Purchase of the marketing authorization and supply agreement with Stragen Pharma S.A. in relation to Paclitaxel OC;

Concurrently with the Purchase Agreement, on May 8, 2013 Resolute Germany entered into an Option Agreement with Oncocorp GmbH relating to the Marketing Authorization of Paclitaxel OC. Pursuant to the agreement our wholly owned subsidiary Resolute Germany acquired an option to purchase from Oncocorp the marketing authorization issued by the German Federal Office for Drugs and Medical Devices ("BfArM") pursuant to the German Drug Act. Transfer of the marketing authorization will require assignment to Resolute Germany of Oncocorp's supply agreement for Paclitaxel OC with STRAGEN Pharma SA. The assignment is subject to the consent of STRAGEN Pharma SA. Pursuant to the Option Agreement, Resolute Germany may request, prior to December 31, 2013, the

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

sale and transfer of the marketing authorization and supply agreement in consideration of a purchase price of €150,000 (approximately USD\$200,100) (plus value added tax, if applicable). As of December 31, 2013, the company did not exercise the option agreement.

On May 8, 2013, concurrent with our acquisition of Resolute Oncology GmbH, we appointed Mr. Peter Gotzler as president of Resolute Oncology GmbH. Mr. Gotzler has over 20 years' experience in pharmaceutical sales, marketing and product management. In 1998, Mr. Gotzler founded Oncocorp GmbH and has since served as its founder and Chief Executive Officer. Since 1995, he has served as director of marketing and sales of AMGEN GmbH, the German subsidiary of AMGEN Inc. From 1988 through 1994 Mr. Gotzler held various positions at ESSEX PHARMA GmbH including Director of the oncology business unit (1992-1994) and senior oncology product manager (1990-1992), Mr. Gotzler holds a Masters in Business Administration from the International Institute for Management Development in Lausanne, Switzerland.

On June 1, 2013, Resolute Germany entered into a Supply Agreement with Oncocorp GmbH pursuant to which Oncocorp GmbH shall be the exclusive supplier to Resolute Germany of Paclitaxel OC in the territory of Germany. The products supplied shall include Paclitaxel 6 milligram/milliliter solution for injection in vials of 30 milligram/5 milliliter, 10mg/16.7ml, 150mg/25ml, and 300mg/50ml. The agreement will allow Resolute Germany, subject to the acquisition of the marketing authorization for Germany contemplated by the Option Agreement with Oncocorp GmbH, to sell Paclitaxel OC under its own name and for its own account. In consideration of the distribution rights granted to Resolute Germany, Oncocorp GmbH shall be entitled to receive a royalty equal to 25% of our gross profits (gross sales, less product rebates, less cost of goods sold) from the sales of all licensed products under the agreement.

The term of the Agreement will commence with effect as of May 1, 2013 and will remain in force until December 31, 2013. The Agreement may be terminated (i) by either party in the event of a default that remains uncured following 30 days' notice by the non-defaulting party, (ii) upon the liquidation, bankruptcy or insolvency of either party, (iii) by written notice to Oncocorp of Oncocorp's failure to maintain the marketing authorization in good standing.

On September 9, 2013, Resolute Oncology Inc. (the "Company") entered into a binding term sheet ("Merger Agreement") which set forth the terms by which Update Pharma Inc. ("Update") would merge with and into the Company. The transaction proposed in the Merger Agreement would have resulted in the Company being the surviving entity with shareholders of Update owning 70% of the Company and shareholders of the Company owning 30%.

On October 15, The Company and Update entered into a new binding term sheet (the "New Agreement") which superseded and replaced the Merger Agreement. Pursuant to the New Agreement, the Company and Update will, subject to the successful completion of a due diligence period, enter into a definitive asset purchase agreement within 45 days of the date hereof which will further define the terms by which Update will acquire all of the assets and liabilities of the Company's European operation, which consist of Resolute Oncology Limited and Resolute Oncology GmbH (the "European Operation"), for a purchase price of 2,500,000 shares of Update's common stock (restricted). The stock will be issued pursuant to an exemption from registration pursuant to Regulation D promulgated under the Securities Act of 1933. The closing of the proposed transaction will be contingent upon certain financing requirements. Upon closing of the proposed transaction, Update will assume the name Resolute Oncology Inc. and continue doing business under that name while the Company will begin doing business under a different name that is yet to be determined.

On March 26, 2014, the Company received written notification of the termination of the binding term sheet, dated October 15, 2013 ("term Sheet"), with Update Pharma Inc. (Update"). The Term Sheet, which had been previously announced, superseded and replaced that certain Merger Agreement, dated September 9, 2013, pursuant to which the Company and Update had intended, subject to certain conditions, to enter into a definitive asset purchase agreement for Update's acquisition of all of the assets and liabilities of the Company's European operation, consisting of Resolute Oncology Limited and Resolute Oncology GmbH.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

On December 12, 2017 Mr. Blair Sorby, the prior President and Director accepted an assignment of the Company's two wholly owned subsidiaries, Resolute Oncology Limited ("Resolute Oncology Ireland"), a company incorporated under the laws of Ireland for the purpose of managing the development of our business in Europe, generally, and Resolute Oncology GmbH, a company incorporated under the laws of Germany. As part of the assignment, Mr. Sorby assumed and indemnified the Company's liabilities. Shortly after, Mr. Sorby appointed Mr. Michael Parisi as the new sole officer and director and resigned from his various positions.

On March 26, 2018, the Company entered into reverse merger agreement with Pupco Brands, Inc. as a result of this agreement Pupco Brands, Inc. become a wholly owned subsidiary of Resolute Oncology, Inc..

On March 26, 2018, Michael Parisi resigned as the sole officer of the company. The same day, the company appointed Mr. Paul Lien as President and Director, Mr. Thomas Elafros as Director and Mr. Pedro Pardo as Treasurer and Secretary.

On March 29, 2018 the name of the company was changed to BestnPet, Inc. As a result, the company now has changed its symbol to "BPET" in the OTC market.

Note 2 - Recent Accounting Pronouncements

The Company has reviewed accounting pronouncements issued during the past two years and have adopted any that are applicable to our company. The Company has determined that none had a material impact on the Company's financial position, results of operations, or cash flows for the period ended March 31, 2018 and December 31, 2017.

Note 3 - Significant Accounting Policies

The following is a summary of significant account policies used in the preparation of these financial statements.

a. Basis of presentation

The financial statements of the Company have been prepared on the accrual basis in accordance with General Accepted Accounting Principles (GAAP) accepted in the United States of America applicable to exploration stage enterprises, and are expressed in U.S. dollars. The Company's fiscal year end is December 31.

b. Basis of consolidation

The consolidated financial statements include the assets, liabilities and expenses of the Company and its wholly owned subsidiary, Pupco Brands, Inc, a company incorporated under the laws of Texas, USA.

c. Cash and cash equivalents

Cash and cash equivalents include highly liquid investments with original maturities of three months or less.

d. Mineral rights, property and acquisition costs

The Company has been in the development stage since its formation on June 23, 2009 and has not yet realized any revenues from its planned operations.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

Mineral exploration costs are expensed as incurred. The costs of acquiring mining properties are capitalized upon acquisition. Mine development costs incurred to develop and expand the capacity of mines, or to develop mine areas in advance of production are also capitalized. Costs incurred, once proven and probable reserves have been established, are capitalized and will be amortized using the unit-of-production method over the life of the mineral rights. Costs incurred to maintain current exploration or to maintain assets on a standby basis are charged to operations. Costs of abandoned projects are charged to operations upon abandonment.

The Company has abandoned its mining project and charged the mining property cost to impairment of mineral interest.

e. Impairment of long-lived assets

The Company reviews and evaluates long-lived assets for impairment when events or changes in circumstances indicate the related carrying amounts may not be recoverable. The assets are subject to impairment consideration under ASC 930-360-35, *Asset Impairment*, as of December 31, 2013, exploration progress has stopped and the mining interest has been impaired.

f. Fair Value of Financial instruments

The Company adopted FASB ASC 820-10-50, "*Fair Value Measurements*. This guidance defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

- Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
- Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

The carrying amounts reported in the balance sheet for the cash and cash equivalents, and current liabilities each qualify as financial instruments and are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest.

g. Income taxes

The Company utilizes the liability method of accounting for income taxes. Under the liability method, deferred income tax assets and liabilities are provided based on the difference between the financial statement and tax bases of assets and liabilities measured by the currently enacted tax rates in effect for the years in which these differences are expected to reverse. Deferred tax expense or benefit is the result of changes in deferred tax assets and liabilities.

h Basic and diluted net loss per share

The Company computes net loss per share in accordance with GAAP. The Company presents both basic and diluted earnings per share ("EPS") on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerators) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all potentially dilutive common shares outstanding during the period using the

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants.

Diluted EPS excludes all potentially dilutive shares if their effect is anti-dilutive. The Company had no common stock equivalents outstanding for the year ended December 31, 2013 and 2012.

	<u>For the period Ended March 31, 2018</u>	<u>For the Year Ended December 31, 2017</u>
Basic Earnings per share:		
Comprehensive income(loss)(numerator)	\$ (180,416)	\$ 259,032
Shares(denominator)	<u>120,242,000</u>	<u>41,446,000</u>
Per share amount	<u>\$ (0.00)</u>	<u>\$ 0.01</u>

	<u>For the period Ended March 31, 2018</u>	<u>For the Year Ended December 31, 2017</u>
Fully Diluted Earnings per share:		
Comprehensive Income(loss)(numerator)	\$ (180,416)	\$ 259,032
Shares(denominator)	<u>120,242,000</u>	<u>41,446,000</u>
Per share amount	<u>\$ (0.00)</u>	<u>\$ 0.00</u>

i. Use of estimates and assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In these financial statements, assets, liabilities and earnings involve extensive reliance on management's estimates. Actual results could differ from those estimates.

ij Concentrations of credit risk

The Company's financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and related party payables. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. At times, its cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company's management also routinely assesses the financial strength and credit worthiness of any parties to which it extends funds and as such, it believes that any associated credit risk exposures are limited.

l. Risks and uncertainties

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

The Company operates in the resource exploration industry that is subject to significant risks and uncertainties, including financial, operational, and other risks associated with operating a resource exploration business, including the potential risk of business failure.

Note 4 – Account Receivables

The Company account receivable of \$26,095 is comprised of one customer at year end December 2016 that was uncollectible. On December 12, 2017, the accounts receivable was part of the demerger of the wholly owned subsidiaries and was assigned to Mr. Sorby and therefore was part of the demerger adjustment. has advanced \$637,585 during the year ended December 31, 2012 to pay for consulting services, legal fees, license and permits, and rights in connection with its ongoing negotiations regarding a potential asset acquisition or business combination with GEN BioPharma Inc. dba Resolute Oncology. At the end of May 2013, the Company abandoned the potential asset acquisition or business combination with GEN BioPharma Inc. dba Resolute Oncology.

The advance on business transaction accumulative total of \$1,434,405 was expensed to discontinued business transaction expense. The accumulative total of \$1,434,405 were comprised of the following expenses, \$777,607 in licensing and rights, \$29,896 in legal, \$490,115 in consulting, and \$136,787 in operating and administration expenses during the year ended December 31, 2013.

Note 5 – Account Receivables

The Company accounts receivable of \$34,138 is comprised of one customer at year end December 31, 2013.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

Note 5 – Intangible Assets

Intangible assets consist of the following at December 31, 2013.

	2016
Licenses for pharmaceutical rights	\$ 321,153
Licenses for pharmaceutical in development	460,620
Licenses for pharmaceutical operations	10,074
Total	<u>791,847</u>
Less: accumulated amortization	<u>(112,090)</u>
Intangible assets-net	<u>\$ 679,757</u>

There were no impairment charges taken during the years ended December 31, 2013.

The estimated useful lives of the Company's intangible assets are as follows:

Intangible Asset	Life
Licenses for pharmaceutical rights	5 years
Licenses for pharmaceutical in development	10 years
Licenses for pharmaceutical operations	5 years

The estimated future amortization expense of intangible assets for the years ended December 31 is as follows:

Fiscal Year ended December 31,	Amount
2014	\$ 40,341
2015	34,878
2016	<u>33,774</u>
Total	<u>\$ 108,993</u>

Note 6 – Related Party Note Payable

The officer of the Company advanced funds at various times from inception to the year ending December 31, 2016 in order to support operations. The total advances as of December 31, 2016 was \$191,895.

On April 29, 2017, the officer released his note with interest. The note payable and accrued interest balance as of December 31, 2017 is 0.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

Note 7 – Convertible Note Payable

On May 9, 2013, the Company borrowed \$350,000 in the form of a convertible note payable with an original maturity date of December 31, 2013 and an annual interest rate of 0.22%. The maturity date has been extended to March 31, 2014. The note is convertible at the lender's option at \$0.50 per share at the maturity date. Conversion of principal is mandatory upon completion of a qualified equity financing of \$10,000,000 or more with interest conversion at the election of the lender. Upon the earlier of a qualified financing or December 31, 2013, the lender will also be entitled to receive 700,000 share purchase warrants with each warrant exercisable for a period of five years for the purchase of 1 common share at \$0.50 per share. The Company determined the note qualified for derivative liability treatment under ASC 815. Accordingly, the company recorded amounts based on their relative fair values which are a debit discount of \$350,000 and a warrant derivative of \$365,415. The fair value of the warrants was determined using the Black-Scholes model and included the following assumptions: risk free rate of 0.08% and an annual volatility of 61%. The discount related to the beneficial conversion feature was amortized to debt discount interest expense for the debit discount over the life of the debt. The warrant was amortized over the life of the note to loss on derivative liability. The Note was issued to one (1) U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), in reliance on Rule 506 of Regulation D of the Securities Act of 1933 on the basis that the investor represented to our company that they were an "accredited investor" as such term is defined in Rule 501(a) of Regulation D. The Company incurred accrued interest of \$2,990.

On November 19, 2013, the bridge loan for \$575,000 was cancelled and reissued as a convertible note payable with the following terms:

On November 19, 2013, the Company borrowed \$575,000 in the form of a convertible note payable with an original maturity date of December 31, 2013 and an annual interest rate of 0.22%. The maturity date has been extended to March 31, 2014. The note is convertible at the lender's option at \$0.50 per share at the maturity date. Conversion of principal is mandatory upon completion of a qualified equity financing of \$10,000,000 or more with interest conversion at the election of the lender. Upon the earlier of a qualified financing or December 31, 2013, the lender will also be entitled to receive 1,150,000 share purchase warrants with each warrant exercisable for a period of five years for the purchase of 1 common share at \$0.50 per share. The Company determined the note qualified for derivative liability treatment under ASC 815. Accordingly, the company recorded amounts based on their relative fair values which are a debit discount of \$460,000 and a warrant derivative of \$499,298. The fair value of the warrants was determined using the Black-Scholes model and included the following assumptions: risk free rate of 0.05% and an annual volatility of 74%. The discount related to the beneficial conversion feature was amortized to debt discount interest expense for the debit discount over the life of the debt. The warrant was amortized over the life of the note to loss on derivative liability. The Note was issued to one (1) U.S. person (at that term as defined in Regulation S of the Securities Act of 1933), in reliance on Rule 506 of Regulation D of the Securities Act of 1933 on the basis that the investor represented to our company that they were an "accredited investor" as such term is defined in Rule 501(a) of Regulation D. The Company accrued interest of \$5,647

On April 29, 2017, both convertible notes were released with its accrued interest. As of December 31, 2017, the total balance on the convertible notes payable and accrued interest was 0.

Note 8 – Derivative Liability

Effective May 8, 2013, the Company adopted ASC 815-40 which defines determining whether an instrument (or embedded feature) is solely indexed to an entity's own stock. The Company borrowed \$350,000 on May 8, 2013 this note is convertible at the holder's option at \$.50 per share. Additionally, the Company issued 700,000 warrants to purchase shares of the Company's common stock at an exercise price of \$.50, expiring 5 years from the date of issuance.

The Company borrowed \$575,000 on November 19, 2013 this note is convertible at the holder's option at \$.50 per

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

share. Additionally, the Company issued 1,150,000 warrants to purchase shares of the Company's common stock at an exercise price of \$.50, expiring 5 years from the date of issuance.

The conversion price of the debt and the exercise price of the warrants are subject to a "reset" provision in the event the Company subsequently issues common stock at a price lower than the effective conversion price of the conversion option or warrant exercise price. If these provisions are triggered, the conversion price of the debt and exercise price of the warrants will be reduced. As a result, the conversion option and warrants are not considered to be solely indexed to the Company's own stock and are not afforded equity treatment.

As of December 31, 2013, the fair values of the warrants were \$864,713 and have been recognized as derivative liabilities on the dates of issuance with all future changes in the fair value of these derivatives being recognized in earnings in the Company's statement of operations under the caption "Other income (expense) – Gain (loss) on derivative liability" until such time as the debt is converted or the warrants are exercised or expire.

The convertible notes payable was released with the warrants. The derivative liability was expensed on April 29, 2017 when the note was released.

Note 9 – Purchase Payable

Per the purchase agreement of Resolute Oncology GmbH, a newly-formed, single product company, from Oncocorp GmbH, and a private pharmaceutical company selling cancer products in Germany, the Company will provide another 250,000 Euros to the owner of Oncocorp over the next five months. These payments have been deferred by verbal agreement of the parties until a mutually agreeable date.

On December 12, 2017 Mr. Blair Sorby, the prior President and Director accepted an assignment of the Company's two wholly owned subsidiaries, Resolute Oncology Limited ("Resolute Oncology Ireland"), a company incorporated under the laws of Ireland for the purpose of managing the development of our business in Europe, generally, and Resolute Oncology GmbH, a company incorporated under the laws of Germany. The purchase payable was part of wholly owned subsidiaries Resolute Oncology GmbH which is owned by Resolute Oncology Limited and therefore was part of the demerger adjustment.

Note 10 - Foreign currency translation

The Company adopted FASB ASC 220-10, "*Comprehensive Income*". This guidance defines comprehensive income which includes net income and other comprehensive income comprising certain specific items previously reported directly in stockholders' equity. Comprehensive income and its components are required to be presented for each year for which an income statement is presented.

As used in FASB ASC 220-10 the term comprehensive income thus encompasses net income. The term other comprehensive income refers to components of comprehensive income that are excluded from net income under GAAP. Note that use of the terms comprehensive income and other comprehensive income per se are not required; thus terms such as non-owner changes in equity and other equivalent descriptions are acceptable. Foreign currency translation adjustment is a component included under other comprehensive income.

The Company's wholly owned subsidiary, Resolute Oncology Limited in Dublin, Ireland, has a functional currency that must be translated into US dollars for the purpose of reporting. The gain or loss from the translation adjustment is reported as part of the comprehensive income which is presented below the total of net income or loss in the income statement.

When the Company has transactional foreign currency fluctuation the gain or loss is recorded above in the net income

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

or loss in the income statement.

Note 11 - Capital Stock

Authorized

The total authorized capital is 412,000,000 common shares with a par value of \$0.001 per common share.

Issued and outstanding

In July 2009 the Company issued 22,000,000 shares of our common stock for cash at \$0.0002 per share

In August 2009 the Company issued 5,500,000 and 5,500,000 shares of our common stock for cash at \$0.0002 and \$0.002 per share, respectively.

In September 2009 the Company issued 2,750,000 and 1,155,000 shares of our common stock for cash at \$0.002 and \$0.01 per share, respectively.

In October 2009 the Company issued 495,000 shares of our common stock for cash at \$0.01 per share.

In December 2012, the Company entered into a private placement offering of our common stock at \$0.50 per share. The Company has collected the proceeds of \$1,208,000 as of December 31, 2013 and has recorded the proceeds as a stock subscription payable under current liabilities until the offering closed on March 14, 2013.

In November 2013, the Company issued 60,000 shares of our commons stock for compensation.

The total stock outstanding at December 31, 2017 is 41,446,000.

In March 26, 2018, the Company entered into reverse merger agreement with Pupco Brands, Inc. and as part of the transaction issue 100,00,000 shares for Pupco Brands's shareholders. Also, 21,362,000 shares were cancelled as part of the agreement.

The total stock outstanding at March 31, 2018 is 120,242,000

Note 12 - Income Taxes

The Financial Accounting Standards Board (FASB) has issued FASB ASC 740-10 (Prior authoritative literature: Financial Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - An Interpretation of FASB Statement No. 109 (FIN 48)). FASB ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with prior literature FASB Statement No. 109, Accounting for Income Taxes. This standard requires a company to determine whether it is more likely than not that a tax position will be sustained will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. As a result of the implementation of this standard, the Company performed a review of its material tax positions in accordance with recognition and measurement standards established by FASB ASC 740-10.

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

The income tax provision differs from the amount of income tax determined by applying the U.S. federal and state income tax rates of 34% to pretax income from continuing operations for the year ended December 31, 2017 and the December 31, 2016 due to the following:

Deferred tax assets and the valuation account are as follows:

	For Year Ended December 31, <u>2017</u>	For Year Ended December 31, <u>2016</u>
Deferred tax asset:		
Net operating loss carryforward	\$ 1,005,447	\$ 1,446,812
Valuation allowance	<u>(1,005,447)</u>	<u>(1,446,812)</u>
Total	\$ -	\$ -

The components of income tax expense are as follows:

	For Year Ended December 31, <u>2017</u>	For Year Ended December 31, <u>2016</u>
Current Federal tax	\$ -	\$ -
Current State tax	-	-
Change in NOL benefit	(90,661)	14,769
Change in valuation allowance	<u>90,661</u>	<u>(14,769)</u>
Total	\$ -	\$ -

The potential income tax benefit of these losses has been offset by a full valuation allowance.

As of December 31, 2017, the Company has an unused net operating loss carry-forward balance of \$2,872,705 that is available to offset future taxable income. This unused net operating loss carry-forward balance begins to expire in 2027.

A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:

	For Year Ended December 31, <u>2017</u>	For Year Ended December 31, <u>2016</u>
--	---	---

BestnPet, Inc.
(Formerly Resolute Oncology, Inc.)
(A Development Stage Company)
Notes to the Consolidated Financial Statement
March 31, 2018 and December 31, 2017

Beginning balance	\$	-	\$	-
Additions based on tax positions related to current year		-		-
Additions for tax positions of prior years		-		-
Reductions for tax positions of prior years		-		-
Reductions in benefit due to income tax expense		-		-
Ending balance	\$	-	\$	-

At December 31, 2017, the Company had no unrecognized tax benefits that, if recognized, would affect the effective tax rate.

The Company did not have any tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the next 12 months.

As of December 31, 2017 and 2016, the Company had no accrued interest or penalties related to uncertain tax positions.

The tax years that remain subject to examination by major taxing jurisdictions are those since inception June 23, 2009 through the year ended December 31, 2017.

Note 13 – Going Concern

These financial statements have been prepared on a going concern basis. The Company has incurred losses since inception resulting in an accumulated deficit of \$3,998,991 and further losses are anticipated in the development of its business. This raises substantial doubt about the Company's ability to continue as a going concern. Its ability to continue as a going concern is dependent upon the ability of the Company to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through a private placement and public offering of its common stock. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

The ability of the Company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, and develop other business ventures.

These factors, among others raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 17 – Subsequent Events

The Company has evaluated subsequent events through the date of issuance of the financial statements and, other than the above described subsequent event, did not have any material recognizable subsequent events after March 31, 2017.